tradingkey.logo
搜索

Hoth Therapeutics Inc

HOTH
添加自选
1.360USD
0.0000.00%
交易中 美东报价延迟15分钟
21.02M总市值
亏损市盈率 TTM

关于 Hoth Therapeutics Inc 公司

Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs. The Company is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT), and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The Company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004), and a treatment for obesity, and obesity-related diseases and conditions (HT-VA).

Hoth Therapeutics Inc简介

公司代码HOTH
公司名称Hoth Therapeutics Inc
上市日期Feb 15, 2019
CEOKnie (Robb)
员工数量2
证券类型Ordinary Share
年结日Feb 15
公司地址1177 Avenue Of The Americas
城市NEW YORK
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编10036
电话16467562997
网址https://hoththerapeutics.com/
公司代码HOTH
上市日期Feb 15, 2019
CEOKnie (Robb)

Hoth Therapeutics Inc公司高管

名称
名称/职务
职务
持股
持股变动
Dr. Jeff Pavell
Dr. Jeff Pavell
Independent Director
Independent Director
5.08K
--
Mr. Wayne Linsley
Mr. Wayne Linsley
Independent Director
Independent Director
134.00
--
Mr. Robb Knie
Mr. Robb Knie
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. David Sarnoff
Mr. David Sarnoff
Independent Director
Independent Director
--
--
Mr. David S. Briones
Mr. David S. Briones
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Chris Camarra
Mr. Chris Camarra
Independent Director
Independent Director
--
--
名称
名称/职务
职务
持股
持股变动
Dr. Jeff Pavell
Dr. Jeff Pavell
Independent Director
Independent Director
5.08K
--
Mr. Wayne Linsley
Mr. Wayne Linsley
Independent Director
Independent Director
134.00
--
Mr. Robb Knie
Mr. Robb Knie
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. David Sarnoff
Mr. David Sarnoff
Independent Director
Independent Director
--
--
Mr. David S. Briones
Mr. David S. Briones
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Chris Camarra
Mr. Chris Camarra
Independent Director
Independent Director
--
--

常见问题

Hoth Therapeutics Inc的前五大股东是谁?

Hoth Therapeutics Inc 的前五大股东如下:Dr. Jeff Pavell

有多少机构持有Hoth Therapeutics Inc(HOTH)的股份?

截至2026Q1,共有43家机构持有Hoth Therapeutics Inc的股份,合计持有的股份价值约为1.30M,占公司总股份的6.79%。与2025Q4相比,机构持股有所增加,增幅为-245182.00。